Your browser doesn't support javascript.
loading
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Xu, Wei; Zhou, Keshu; Wang, Tingyu; Yang, Shenmiao; Liu, Lihong; Hu, Yu; Zhang, Wei; Ding, Kaiyang; Zhou, Jianfeng; Gao, Sujun; Xu, Bing; Zhu, Zunmin; Liu, Ting; Zhang, Huilai; Hu, Jianda; Ji, Chunyan; Wang, Shunqing; Xia, Zhongjun; Wang, Xin; Li, Yan; Song, Yongping; Ma, Shuo; Tang, Xinran; Zhang, Bin; Li, Jianyong.
Afiliação
  • Xu W; Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, People's Republic of China.
  • Zhou K; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Wang T; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of Chin
  • Yang S; Department of Hematology, Peking University People's Hospital, Beijing, People's Republic of China.
  • Liu L; Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Hu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Zhang W; Department of Hematology, Peking Union Medical College Hospital, Beijing, People's Republic of China.
  • Ding K; Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
  • Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Gao S; Department of Hematology, The First Hospital, Jilin University, Jilin, People's Republic of China.
  • Xu B; Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
  • Zhu Z; Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China.
  • Liu T; Department of Hematology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
  • Zhang H; Lymphoma, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Hu J; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Ji C; Department of Hematology, Qilu Hospital, Shandong University Jinan, Jinan, People's Republic of China.
  • Wang S; Department of Hematology, Guangzhou First People's Hospital, Guangzhou, People's Republic of China.
  • Xia Z; Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, People's Republic of China.
  • Wang X; Department of Hematology, Shandong Provincial Hospital, Jinan, People's Republic of China.
  • Li Y; Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
  • Song Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Ma S; Department of Clinical Development, InnoCare Pharma Limited, Beijing, People's Republic of China.
  • Tang X; Department of Clinical Development, InnoCare Pharma Limited, Beijing, People's Republic of China.
  • Zhang B; Department of Clinical Development, InnoCare Pharma Limited, Beijing, People's Republic of China.
  • Li J; Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, People's Republic of China.
Am J Hematol ; 98(4): 571-579, 2023 04.
Article em En | MEDLINE | ID: mdl-36683422
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article